In patients with neovascular, age-related macular degeneration, improvements in visual acuity as a result of intravitreal injections of aflibercept were maintained out to 96 weeks in the phase 3 VIEW 1 and VIEW 2 trials, according to an update presented at the American Academy of Ophthalmology (AAO) and Asia-Pacific Academy of Ophthalmology 2012 Joint Meeting. "Visual and anatomic improvements observed at Week 52 were largely maintained through Week 96 with modified quarterly dosing," reported Peter Kaiser, MD, from the Cleveland Clinic, Ohio. "The efficacy of aflibercept 2.0 mg given every 2 months was similar to monthly ranibizumab." To see more details visit,
www.medscape.com